The differential diagnosis of the metastatic axillary lymphadenopathies of breast cancer with which they occur secondary to the Pfizer-BioNTech vaccine against COVID-19, is imperative. In a series of cases, we analyzed the characteristics of unilateral axillary lymphadenopathy in patients after Pfizer-BioNTech vaccination. Axillary lymphadenopathy were observed ipsilateral to the vaccination arm. The axillary ultrasound defined these as reactive and that they disappeared in 3 weeks. The pathological findings were benign. The anamnesis, the place and date of vaccination and the radiological findings, play an essential role to carry out a correct differential diagnosis and follow-up of these adenopathies.
CITATION STYLE
De Armas-Conde, M., Sanchez-Alvarez, A. L., Tejera-Hernandez, A., Vega-Benitez, V., Antela-Lopez, J. C., Isabel Gutierrez-Giner, M., & Hernandez-Hernandez, J. R. (2022). Post-vaccination SARS-CoV-2 axillary adenopathy. Differences with axillary metastases from breast cancer. Cirugia y Cirujanos (English Edition), 90(3), 410–413. https://doi.org/10.24875/CIRU.21000737
Mendeley helps you to discover research relevant for your work.